**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 45055**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

**MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation**

Zhang Z *et al*. Role of miR-596 in GC

Zhen Zhang, Dong-Qiu Dai

**Zhen Zhang, Dong-Qiu Dai,** Department of Gastroenterological Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China

**ORCID number:** Zhen Zhang (0000-0001-6586-4625); Dong-Qiu Dai (0000-0002-1154-3276).

**Author contributions:** Dai DQ designed this study; Zhang Z performed the experiments and analyzed the data; Dai DQ and Zhang Z drafted the article, made critical revisions related to the intellectual content of the manuscript, and approved the final version of the article to be published.

**Supported by** National Natural Science Foundation of China, No. 30572162; and Natural Science Foundation of Liaoning Province, No. 201602817.

**Institutional review board statement:** All gastric cancer specimens from the patients were taken after informed consent and ethical permission were obtained for participation in the study.

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest related to this study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Dong-Qiu Dai, PhD, Chief Doctor, Professor, Surgical Oncologist,** Department of Gastroenterological Surgery, the Fourth Affiliated Hospital of China Medical University, 4 Chongshan Road, Shenyang 110032, Liaoning Province, China. daidq63@163.com

**Telephone:** +86-24-62043110

**Fax:** +86-24-62043110

**Received:** December 11, 2018

**Peer-review started:** December 11, 2018

**First decision:** December 28, 2018

**Revised:** January 27, 2019

**Accepted:** January 28, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

In the present study, we investigated a suppressive role of microRNA-596 (miR-596) in gastric cancer (GC). Moreover, the downregulation of miR-596 in GC cell lines was associated with an increase of miR-596 promoter methylation. We also established that miR-596 controls the expression of peroxiredoxin 1 (PRDX1), which has never been reported before, suggesting that this interaction could play an important role in GC progression.

***AIM***

To study the potential role and possible regulatory mechanism of miR-596 in GC.

***METHODS***

The expression levels of miR-596 and PRDX1 in gastric cancer tissues and cell lines were detected by quantitative real-time PCR (qRT-PCR). Western blot and luciferase reporter assay were used to detect the effect of miR-596 on PRDX1 expression. Then, the proliferation, metastasis, and invasion of GC cell lines transfected with miR-596 mimic were analyzed, respectively, by Cell Counting Kit-8 proliferation assay, wound healing assay, and transwell invasion assay. Meanwhile, the methylation status of the promoter CpG islands of miR-596 in GC cell lines was detected by methylation-specific PCR (MSP).

***RESULTS***

Expression of miR-596 was decreased and PRDX1 was upregulated in GC tissues and cell lines. Overexpression of miR-596 decreased the expression of PRDX1 and luciferase reporter assays detected the direct binding of miR-596 to the 3'-untranslated region (UTR) of PRDX1 transcripts. Furthermore, we found that overexpression of miR-596 remarkably suppressed cell proliferation, migration, and invasion in GC cells. We further analyzed miR-596 promoter methylation by MSP and qRT-PCR, and found the downregulation of miR-596 was associated with promoter methylation status in GC cell lines. Moreover, DNA demethylation and reactivation of miR-596 after treatment with 5-Aza-2’-deoxycytidine inhibited the proliferative ability of GC cells.

***CONCLUSION***

MiR-596 has a tumor suppressive role in GC and is downregulated partly due to promoter hypermethylation. Furthermore, PRDX1 is one of the putative target genes of miR-596.

**Key words:** Gastric cancer; MicroRNA-596; Methylation; Peroxiredoxin 1

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In the present study, we investigated a suppressive role of microRNA-596 (miR-596) in gastric cancer (GC). MiR-596 was downregulated in human specimens of GC and GC cell lines, and overexpression of miR-596 significantly reduced GC cell proliferation. Downregulation of miR-596 in GC cell lines was associated with an increase of miR-596 promoter methylation. We also established that miR-596 controls the expression of peroxiredoxin 1, which has never been reported before, suggesting that this interaction could play an important role in GC progression. Overall, this study has an impact in understanding the role of miRNAs in cancer progression.

Zhang Z, Dai DQ. MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Gastric cancer (GC) is one of the most common digestive malignancies and remains the second most common cause of cancer-related mortality worldwide[1]. Currently, most patients are diagnosed at an advanced stage, leading to a low cure rate and a low 5-year survival rate. Therefore, it is necessary to further study the molecular mechanism of GC and identify more effective biomarkers for the diagnosis and treatment of GC. A greater understanding of these factors will play an important role in early diagnosis and treatment of GC and improvement of prognosis.

MicroRNAs (miRNAs) are a class of endogenous non-coding RNA with a length of approximately 23 nucleotides, which can bind to complementary sequences in the 3'-untranslated regions (UTRs) of specific mRNAs, resulting in degradation of target mRNAs or inhibition of their translation into functional proteins[2]. Accumulating studies have indicated that miRNAs have been associated with almost all known physiological and pathological processes, including cancer[3,4]. In addition, it is suggested in recent studies that epigenetic modification, especially DNA methylation, is one of many mechanisms of miRNA suppression in human cancer[5,6]. MicroRNA-596 (miR-596) is located on human chromosome 8p23.3 and is an intergenic miRNA gene. In recent years, studies have found that miR-596 is downregulated in a variety of cancers, such as oral cancer[7], endometrial cancer[8], melanoma[9], and bladder cancer[ 10 , 11 ]. Additionally, miR-596 was previously found to be silenced by promoter CpG island hypermethylation in hepatocellular carcinoma[12,13], endometrial cancer[14], and oral cancer[7]. In GC, Song *et al*[15] reported that miR-596 had low expression and could target CLDN4 to inhibit the invasion of GC cells. However, whether the expression of miR-596 is associated with promoter methylation alteration in GC remains unclear and whether other targets of miR-596 exist in GC remains to be studied.

In this study, we confirmed that the expression of miR-596 was markedly downregulated in GC tissues and cell lines. Upregulation of miR-596 suppressed the proliferation, migration, and invasion of GC cells. The decreased expression of miR-596 was associated with promoter DNA methylation in GC. Moreover, it was indicated that peroxiredoxin 1 (PRDX1) is one of the putative targets of miR-596 in GC. All these results suggest that there is a critical role for miR-596 in the pathogenesis of GC and it may serve as a potential therapeutic target for patients with this disease.

**MATERIALS AND METHODS**

***Human tissue samples***

A total of 55 paired surgically resected GC tissues and adjacent normal gastric tissues, which were diagnosed by an independent pathologist, were collected from the Fourth Affiliated Hospital of China Medical University, between 2014 and 2015. The specimens were promptly collected following surgery and all were pathologically confirmed. None of the patients enrolled in this study had previously received preoperative chemotherapy or radiotherapy. Informed consent was obtained from all patients. The Medical Association Ethics Committee of the Fourth Affiliated Hospital of China Medical University approved all aspects of the present study in accordance with the Helsinki Declaration.

***Gastric cells and culture***

One immortalized normal gastric cell line (GES-1) and four human GC cell lines (AGS, SGC-7901, MKN-45, and MGC803) were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). These cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, United States) containing 10% fetal bovine serum (Invitrogen) in a humidified atmosphere of 5% CO2 at 37 ℃.

***RNA isolation and quantitative real-time PCR (qRT-PCR)***

Total RNA was extracted from tissues or cultured cells using Trizol reagent (Invitrogen). According to the protocol of the Poly(A) Tailing Kit (Tiangen, Beijing, China), poly(A) tails were added to the miRNA. The PrimeScriptTM RT reagent Kit with gDNA Eraser (Takara, Dalian, China) and gene-specific primers or random primers were used to generate cDNA. Real-time PCR was performed in a Light Cycler 480 II Real-Time PCR system (Roche Diagnostics, Basel, Switzerland) using SYBR® Green (Takara). Glyceraldehyde phosphate dehydrogenase (GAPDH) and U6 snRNA were employed as endogenous controls for mRNA and miRNA, respectively. The comparative Ct method was used to calculate the relative expression of RNA. Primer sequences are displayed in Table 1.

***Western blot analysis***

Transfected cells were lysed with lysis buffer (Beyotime, Shanghai, China) containing 1 mmol/L PMSF. The protein concentrations were measured using the bicinchoninic-acid (BCA) protein assay kit (Beyotime). Equal amounts (30 μg) of protein were separated by 15% SDS-PAGE and electro-transferred to PVDF membranes (Millipore), which were then incubated with primary antibodies against PRDX1 (1:500 dilution; Proteintech, Wuhan, China) and β-actin (1:1000 dilution; Proteintech) overnight at 4 ℃. After incubation with peroxidase-conjugated affinipure goat anti-rabbit IgG or peroxidase-conjugated affinipure goat anti-mouse IgG (Beyotime), the bands were visualized using an electrochemiluminescence (ECL) detection kit (ThermoBiotech Inc, Rockford, IL, United States). Protein bands were scanned and quantified using densitometric software (Bio-Rad, California, United States).

***Transfection***

Transfections were performed using the Lipofectamine3000 Reagent (Invitrogen) according to the manufacturer’s protocol. Final concentrations of 50 nmol/L of miR-596 mimic (5'-AAGCCUGCCCGGCUCCUCGGG-3’)/ miR-NC (5'-UUGUACUA CACAAAAGUACUG-3’) and 0.75 μg/mL plasmids were used for each transfection in a six-well plate with 2 mL culture medium. Total RNA and protein were collected 48 h after transfection.

***Luciferase reporter assay***

MiR-596 mimic or miR-NC, reporter construct, or control vector was cotransfected into MGC-803 cells for 48 h. Dual luciferase Reporter GeneMAssay Kit (Tiangen, Beijing, China) was used to detect luciferase activity. Each test was repeated three times.

***Cell Counting Kit-8 proliferation assay***

Cell proliferation was determined with the Cell Counting Kit-8 (CCK-8) kit (Dojindo, Japan); 3000 cells were seeded into 96-well plates for 24 h and then treated with NC, miR-NC, or miR-596 mimic. After 0, 24, 48, and 72 h of treatment, 100 μL cultural supernatant was collected to another 96-well plate and then 10 μL CCK-8 solution was added for incubation at 37 ℃ for 4 h. The absorbance was measured at 450 nm wavelength using spectrophotometry (BioTek, United States).

***Wound healing assay***

Cells were seeded in six-well plates and treated with NC, miR-NC, or miR-596 mimic. Linear scratch wounds were created on cell monolayers with a sterile 200 μL pipette tip, and the scratched areas were photographed at × 100 magnification using a Leica DMI3000B computer-assisted microscope (Leica, Buffalo Grove, United States). Images were captured at 0, 24, 48, and 72 h after the scratch was made. Images were analyzed using Image-Pro Plus v6.0 image analysis software (Media Cybernetics, Rockville, MD, United States).

***In vitro invasion assay***

Transwell plates (BD, Biosciences, United States) were used for GC cell invasion assay. The bottom chamber contained complete medium and the upper chamber has serum-free medium. Matrigel (BD) was added to the RPMI 1640 medium for detecting invading cells. After transfection with NC, miR-NC, or miR-596 mimic, GC cells were appropriately seeded into the cell culture. After incubation at 37 ℃ for 24 h, the invaded cells were fixed and stained using Giemsa. The images of cells were photographed with a microscope (Leica) at × 100 magnification and the cell number counted in three random fields of view. The results are presented as a column graph with statistics.

***DNA extraction and*** ***methylation-specific PCR (MSP)***

Genomic DNA was extracted from the cultured cells by SDS/proteinase K treatment, followed by phenol–chloroform extraction and ethanol precipitation. The bisulfite treatment was performed using the kit EZ DNA Methylation-Gold Kit (Zymo Research, CA, United States) according to the manufacturer’s protocol. The methylated primers were 5’-GAG GTT CGG GAT GTA TCG TT-3’ (forward) and 5’-TAA CTT CCG CAA TAA CCG TAT-3’ (reverse), which result in a 193 bp band; the unmethylated primers were 5’-GTG GAG GTT TGG GAT GTA TTG-3’(forward) and 5’-CTC TTA ACT TCC ACA ATA ACC ATA-3’ (reverse), which result in a 200 bp band. The PCR reaction conditions were as follows: 94 ℃ for 5 min, 40 cycles of 94 ℃ for 30 s, 56 ℃ for 30 s, and 72 ℃ for 45 s, and 72 ℃ for 10 min. Agarose gel electrophoresis and ethidium bromide staining were then performed. Data from the gels were collected with a laser density scanner (Pharmacia LKB Ultroscan) and subsequently analyzed. All experiments were repeated three times, and the mean value was used for statistical analysis.

***5-Aza-2’-deoxycytidine (5-Aza-dC) treatment***

GC cells were seeded at 5 × 105 cells per well in six-well culture plates and cultured in RPMI 1640 medium (Invitrogen) containing 10% fetal bovine serum in a humidified atmosphere of 5% CO2 at 37 ℃ for 24 h. The cells were incubated in culture medium with 0, 2.5, 5, or 10 μmol/L of 5-Aza-dC (Sigma, Shanghai, China) for 3 d, with daily medium replacement. After that, total RNA and DNA were isolated from these treated cells for qRT-PCR and MSP analysis, respectively.

***Cell viability assay***

GC cells were seeded on 96-well plates and treated with different concentrations of 5-Aza-dC in triplicate. After 24, 48, 72, or 144 h of incubation, cells were washed using PBS and cultured in 100 mL RPMI 1640, including 10 mL CCK-8 solution for another 4 h. The absorbance at 450 nm was measured using spectrophotometry (BioTek).

***Statistical analysis***

All statistical analyses were performed with SPSS 17.0 software package (SPSS, Chicago, IL, United States). Data are expressed as the mean ± SD. *χ2* test, Student’s *t* test, and one-way ANOVA analysis were used for comparisons. *P*-values < 0.05 were considered statistically significant.

**RESULTS**

***MiR-596 is downregulated and PRDX1 upregulated in GC tissues and cell lines***

In the present study, the levels of miR-596 expression in 55 pairs of GC and normal control tissues and cell lines were initially assessed using qRT-PCR. The results demonstrated that miR-596 was significantly downregulated in GC tissues compared with paired control tissues (Figure 1A). Furthermore, endogenous expression of miR-596 was investigated in different gastric cell lines, including AGS, SGC-7901, MKN-45, MGC-803, and GES-1. It was shown that the GC cell lines (AGS, SGC-7901, MKN-45, and MGC-803) exhibited relatively low miR-596 expression levels compared to the normal gastric cell line GES-1 (Figure 1B). In addition, PRDX1 expression was analyzed in 55 paired GC and control tissues and cell lines by qRT-PCR. The results indicated that PRDX1 expression was significantly upregulated in GC tissues and cell lines when compared to corresponding non-tumorous tissue and the normal gastric cell line GES-1 (Figure 1C and D). Moreover, Pearson's correlation analysis revealed that the expression of miR-596 was inversely correlated with PRDX1 in GC tissues (Figure 1E). Then, we further examined the relationship between miR-596 expression and clinicopathological factors in 55 GC tissues by Pearson's *χ2* test. MiR-596 expression was significantly related to tumor differentiation grade and TNM stage, but not with age, sex, tumor size, tumor site, Borrmann type, or lymph node metastasis (Table 2).

***PRDX1 as a putative target of miR-596***

Using three bioinformatic databases (TargetScan, miRWalk, and miRanda), PRDX1 was selected as a predicted target gene of miR-596 (Figure 2A). PRDX1 expression was analyzed in GC cell lines and the GES-1 cell line by Western blot. The results indicated that PRDX1 expression was significantly upregulated in GC cell lines when compared to the normal gastric cell lines GES-1 (Figure 2B). To further validate this prediction, miR-NC or miR-596 mimic was co-transfected into MKN-45 and MGC-803 cell lines and cultured for 48 h. qRT-PCR and Western blot analysis approved that overexpression of miR-596 (Figure 2C) significantly inhibited PRDX1 expression at the mRNA and protein levels in MKN-45 and MGC-803 cell lines (Figure 2D). Furthermore, the luciferase activity of the PRDX1\_WT vector was significantly suppressed by the miR-596 mimic, but miR-596 mimic could not affect the luciferase activity of PRDX1\_MUT vector or the miR-NC (Figure 2E). These results suggested that miR-596 may bind directly to PRDX1 and inhibit its expression.

***MiR-596 suppresses GC cell proliferation***

To investigate the role of miR-596 in GC cell proliferation, we utilized ectopic expression of miR-596 and measured cell growth of two GC cell lines MKN-45 and MGC-803 using the CCK-8 method. The results revealed that cell proliferation was clearly suppressed in MKN-45 (Figure 3A) and MGC-803 (Figure 3B) cells after manipulation of miR-596 mimic at 48 and 72 h, but no significant difference was observed at 24 h.

***MiR-596 inhibits GC cell migration and invasion***

To further evaluate the role of miR-596 in the progression and metastasis of GC, we performed wound healing and Transwell invasion assays in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimic. Transfection with miR-596 mimic significantly suppressed cell migration (Figure 4A and B) and invasion (Figure 4C) in the MKN-45 and MGC-803 cells compared to the NC and miR-NC groups.

***MiR-596 is regulated by epigenetic mechanisms in GC***

First, to detect whether low expression of miR-596 is related to DNA methylation, we detected the DNA methylation status of miR-596 promoter region in GC cell lines. Data from our MSP analysis displayed that there was a significant negative correlation between miR-596 promoter methylation and expression levels in GC cell lines (Figure 5A). Meanwhile, we treated the miR-596-silenced cell lines, MKN-45 and MGC-803, with the demethylating agent 5-Aza-dC, to confirm whether miR-596 expression could be restarted. We observed that the methylation status of miR-596 promoter region was significantly decreased in MKN-45 and MGC-803 cells after treatment with 5-Aza-dC, the expression of miR-596 was obviously increased, and the highest expression occurred at a concentration of 5 μmol/L (Figure 5B). Moreover, it was found that the expression of PRDX1 mRNA was slightly upregulated in MKN-45 and MGC-803 cells after treatment with 5-Aza-dC, but the expression of PRDX1 protein was significantly downregulated (Figure 5C). MSP products were sequenced, which confirmed that sodium bisulfite modification was sufficient for DNA (Figure 5D).

***5-Aza-dC treatment decreases proliferation in GC cell lines***

To evaluate whether 5-Aza-dC treatment affects GC cell growth, we analyzed the proliferation of MKN-45 (Figure 6A) and MGC-803 (Figure 6B) cells treated with 5-Aza-dC. The results of the CCK-8 assay showed that the cell inhibition rate was significantly increased as the 5-Aza-dC concentration or the culture time was increased as compared with the untreated control group.

**DISCUSSION**

Accumulating evidence has demonstrated that miRNAs may play an important role in GC initiation and development[16,17]. In the present study, we found that miR-596 expression was significantly decreased in GC tissue and cell lines. Moreover, artificial ectopic expression of miR-596 potentially suppressed GC cell proliferation, migration, and invasion. This indicates that miR-596 may function as a tumor suppressor in GC and that miR-596 expression may contribute to the development of GC.

MiRNAs are dysregulated in nearly all human tumours and can function as either tumour suppressors or oncogenes, depending on their target transcripts[18,19]. They work by binding to complementary sequences in the 3'-UTRs of specific mRNAs, leading to translation inhibition[20]. Moreover, due to a non-strict hybridization of the seed match region, one miRNA can bind to multiple mRNA targets, allowing simultaneous downregulation of multiple target mRNAs. Similarly, multiple miRNAs can bind to the same mRNA target and enhance translational repression[21,22]. In our research, bioinformatic analysis show that PRDX1 is a potential target of miR-596. PRDX1 belongs to the peroxiredoxin family and is composed of thiol-specific antioxidant enzymes, which can reduce H2O2 and alkyl hydroperoxide[23], and is related to the reduction of oxidative damage[24]. PRDX1 overexpression was associated with tumor growth and poor prognosis in numerous cancers including breast cancer[25], lung cancer[26], and esophageal squamous cell cancer[27]. However, the expression profile and potential role of PRDX1 in GC remain to be investigated. In this study, we found that the expression of PRDX1 was substantially upregulated in cancer tissues and cell lines by qRT-PCR and was inversely correlated with miR-596 in GC tissues. Additionally, the results showed that overexpression of miR-596 decreased the expression of PRDX1 and luciferase reporter assays detected the direct binding of miR-596 to the 3'-UTR of PRDX1 transcripts. Our results provided a theoretical basis for further study of the mechanism of miR-596 and PRDX1 in GC.

Previous studies showed that transcription of miRNAs can also be epigenetically regulated by methylation in CpG islands[28,29]. In addition, DNA methylation is a reversible signal, similar to other physiological biochemical modifications[30]. The silencing of tumor suppressor genes is closely related to DNA hypermethylation and can be effectively reversed by DNA methyltransferase inhibitors, thereby inhibiting tumor growth[31]. In the present research, DNA methylation analysis by MSP indicated that there was a markedly negative correlation between miR-596 promoter methylation and expression levels in GC cell lines. Furthermore, treatment with the demethylating agent 5-Aza-dC raised the expression of miR-596 in GC cell lines. In addition, the expression of its target gene PRDX1 protein was significantly downregulated. These results showed that the downregulation of miR-596 in GC is attributed, at least in part, to the hypermethylation of CpG sequences in its promoter.

5-Aza-dC as a demethylating agent has been recently used for treatment of myelodysplastic syndromes and acute myelomonocytic leukemia[32]. The main mechanism of 5-Aza-dC is to reduce its activity by binding to DNA methyltransferase I (DNMT1), selectively induce DNMT degradation, and inhibit tumor growth by inducing apoptosis, affecting cell cycle and cytotoxicity[33]. Moreover, 5-Aza-dC is cytotoxic at high concentrations and demethylated at low concentrations[34]. Therefore, our study suggested that the inhibitory effect of 5-Aza-dC on the proliferative ability of GC cells may be due in part to the demethylation and reactivation of miR-596.

In conclusion, our current study demonstrated that the expression of miR-596 was downregulated in GC cells and GC tissues. The *in vitro* data further suggested that miR-596 expression was able to inhibit GC cell growth, migration, and invasion. Furthermore, miR-596 expression was regulated by epigenetic mechanisms. The downregulation of miR-596 was associated with promoter methylation status in GC cell lines. DNA demethylation and reactivation of miR-596 after treatment with 5-Aza-dC inhibited the proliferative ability of GC cells. Moreover, we identified that PRDX1 is one of the putative target genes of miR-596. Our results further emphasize that miR-596 functions as a crucial tumor suppressor that is regulated by epigenetic mechanisms in GC and may offer a promising novel therapeutic approach for GC. Nonetheless, more studies are required to determine the precise mechanism of miR-596 in the progression of GC.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is one of the most common digestive malignancies and remains the second most common cause of cancer-related mortality worldwide. Currently, most patients are diagnosed at an advanced stage, leading to a low cure rate and a low 5-year survival rate. Therefore, it is necessary to further study the molecular mechanism of GC and identify more effective biomarkers for the diagnosis and treatment of GC.

***Research motivation***

Accumulating studies have indicated that microRNAs (miRNAs) have been associated with almost all known physiological and pathological processes, including cancer. In addition, it is suggested in recent studies that epigenetic modification, especially DNA methylation, is one of many mechanisms of miRNA suppression in human cancer. A greater understanding of these factors will play an important role in early diagnosis and treatment of GC and improvement of prognosis.

***Research objectives***

To study the potential role and possible regulatory mechanism of microRNA-596 (miR-596) in GC, and whether other targets of miR-596 exist in GC.

***Research methods***

In the present study, the levels of miR-596 expression in 55 pairs of GC and normal control tissues and cell lines were initially assessed using quantitative real-time (qRT-PCR). We further examined the relationship between miR-596 expression and clinicopathological factors in 55 GC tissues by Pearson's *χ2* test. In addition, peroxiredoxin 1 (PRDX1) expression was analyzed in 55 paired GC and control tissues and cell lines by qRT-PCR. Western blot and luciferase reporter assay were used to detect the effect of miR-596 on PRDX1 expression. Then, the proliferation, metastasis, and invasion of GC cells transfected with miR-596 mimic were analyzed, respectively, by Cell Counting Kit-8 proliferation assay, wound healing assay, and transwell invasion assay. The methylation status of the promoter CpG islands of miR-596 in GC cell lines was detected by methylation-specific PCR. Meanwhile, we treated GC cells with the demethylating agent 5-Aza-2’-deoxycytidine (5-Aza-dC) to confirm whether miR-596 expression could be restarted. Finally, in order to evaluate whether 5-Aza-dC treatmentaffects GC cell growth, we analyzed the proliferation of GC cells treated with 5-Aza-dC.

***Research results***

# Our current study demonstrated that the expression of miR-596 was downregulated in GC cells and GC tissues. The *in vitro* data further suggested that miR-596 expression was able to inhibit GC cell growth, migration, and invasion. Furthermore, miR-596 expression was regulated by epigenetic mechanisms. Moreover, we identified that PRDX1 is one of the putative target genes of miR-596.

***Research conclusions***

In the present study, we have investigated a suppressive role of microRNA-596 in GC. We reported that miR-596 was downregulated in human specimens of GC and GC cell lines, and that overexpression of miR-596 significantly reduced GC cell proliferation. Moreover, the downregulation of miR-596 in GC cell lines was associated with an increase of miR-596 promoter methylation. We also established that miR-596 controls the expression of PRDX1, which has never been reported before, suggesting that this interaction could play an important role in GC progression.

***Research perspectives***

Our results further emphasize that miR-596 functions as a crucial tumor suppressor that is regulated by epigenetic mechanisms in GC and may offer a promising novel therapeutic approach for GC. Nonetheless, more studies are required to determine the precise mechanism of miR-596 in the progression of GC.

**REFERENCES**

1 **Global Burden of Disease Cancer Collaboration**, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. *JAMA Oncol* 2015; **1**: 505-527 [PMID: 26181261 DOI: 10.1001/jamaoncol.2015.0735]

2 **Bartel DP**. MicroRNAs: target recognition and regulatory functions. *Cell* 2009; **136**: 215-233 [PMID: 19167326 DOI: 10.1016/j.cell.2009.01.002]

3 **Lujambio A**, Lowe SW. The microcosmos of cancer. *Nature* 2012; **482**: 347-355 [PMID: 22337054 DOI: 10.1038/nature10888]

4 **Mendell JT**, Olson EN. MicroRNAs in stress signaling and human disease. *Cell* 2012; **148**: 1172-1187 [PMID: 22424228 DOI: 10.1016/j.cell.2012.02.005]

5 **Lopez-Serra P**, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. *Oncogene* 2012; **31**: 1609-1622 [PMID: 21860412 DOI: 10.1038/onc.2011.354]

6 **Lujambio A**, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. *Cell Cycle* 2007; **6**: 1455-1459 [PMID: 17581274]

7 **Endo H**, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J, Kozaki K. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. *Carcinogenesis* 2013; **34**: 560-569 [PMID: 23233740 DOI: 10.1093/carcin/bgs376]

8 **Ma M**, Yang J, Wang B, Zhao Z, Xi JJ. High-Throughput Identification of miR-596 Inducing p53-Mediated Apoptosis in HeLa and HCT116 Cells Using Cell Microarray. *SLAS Technol* 2017; **22**: 636-645 [PMID: 28732184 DOI: 10.1177/2472630317720870]

9 **Liu SM**, Lin CH, Lu J, Lin IY, Tsai MS, Chen MH, Ma N. miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death. *J Invest Dermatol* 2018; **138**: 911-921 [PMID: 29183729 DOI: 10.1016/j.jid.2017.11.016]

10 **Olivieri M**, Ferro M, Terreri S, Durso M, Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D, Vannini I, Marinelli L, Novellino E, Zhang W, Incoronato M, Ilardi G, Staibano S, Marra L, Franco R, Perdonà S, Terracciano D, Czerniak B, Liguori GL, Colonna V, Fabbri M, Febbraio F, Calin GA, Cimmino A. Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. *Oncotarget* 2016; **7**: 20636-20654 [PMID: 26943042 DOI: 10.18632/oncotarget.7833]

11 **Terreri S**, Durso M, Colonna V, Romanelli A, Terracciano D, Ferro M, Perdonà S, Castaldo L, Febbraio F, de Nigris F, Cimmino A. New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. *Genes (Basel)* 2016; **7**: [PMID: 27983635 DOI: 10.3390/genes7120127]

12 **Anwar SL**, Albat C, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H, Lehmann U. Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. *Int J Cancer* 2013; **133**: 660-670 [PMID: 23364900 DOI: 10.1002/ijc.28068]

13 **Potapova A**, Albat C, Hasemeier B, Haeussler K, Lamprecht S, Suerbaum S, Kreipe H, Lehmann U. Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. *BMC Biotechnol* 2011; **11**: 6 [PMID: 21235780 DOI: 10.1186/1472-6750-11-6]

14 **Huang YW**, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS. Hypermethylation of miR-203 in endometrial carcinomas. *Gynecol Oncol* 2014; **133**: 340-345 [PMID: 24530564 DOI: 10.1016/j.ygyno.2014.02.009]

15 **Song YX**, Sun JX, Zhao JH, Yang YC, Shi JX, Wu ZH, Chen XW, Gao P, Miao ZF, Wang ZN. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. *Nat Commun* 2017; **8**: 289 [PMID: 28819095 DOI: 10.1038/s41467-017-00304-1]

16 **Ueda T**, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. *Lancet Oncol* 2010; **11**: 136-146 [PMID: 20022810 DOI: 10.1016/S1470-2045(09)70343-2]

17 **Kiga K**, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, Kim M, Ogawa M, Iwasaki YW, Kayo H, Fukuda-Yuzawa Y, Yashiro M, Fukayama M, Fukao T, Sasakawa C. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. *Nat Commun* 2014; **5**: 4497 [PMID: 25187177 DOI: 10.1038/ncomms5497]

18 **Di Leva G**, Garofalo M, Croce CM. MicroRNAs in cancer. *Annu Rev Pathol* 2014; **9**: 287-314 [PMID: 24079833 DOI: 10.1146/annurev-pathol-012513-104715]

19 **Kwan JY**, Psarianos P, Bruce JP, Yip KW, Liu FF. The complexity of microRNAs in human cancer. *J Radiat Res* 2016; **57** Suppl 1: i106-i111 [PMID: 26983984 DOI: 10.1093/jrr/rrw009]

20 **Gu S**, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. *Nat Struct Mol Biol* 2009; **16**: 144-150 [PMID: 19182800 DOI: 10.1038/nsmb.1552]

21 **Ameres SL**, Zamore PD. Diversifying microRNA sequence and function. *Nat Rev Mol Cell Biol* 2013; **14**: 475-488 [PMID: 23800994 DOI: 10.1038/nrm3611]

22 **Pinweha P**, Rattanapornsompong K, Charoensawan V, Jitrapakdee S. MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. *Comput Struct Biotechnol J* 2016; **14**: 223-233 [PMID: 27358718 DOI: 10.1016/j.csbj.2016.05.005]

23 **Kim JH**, Lee JM, Lee HN, Kim EK, Ha B, Ahn SM, Jang HH, Lee SY. RNA-binding properties and RNA chaperone activity of human peroxiredoxin 1. *Biochem Biophys Res Commun* 2012; **425**: 730-734 [PMID: 22877757 DOI: 10.1016/j.bbrc.2012.07.142]

24 **Aeby E**, Ahmed W, Redon S, Simanis V, Lingner J. Peroxiredoxin 1 Protects Telomeres from Oxidative Damage and Preserves Telomeric DNA for Extension by Telomerase. *Cell Rep* 2016; **17**: 3107-3114 [PMID: 28009281 DOI: 10.1016/j.celrep.2016.11.071]

25 **Cha MK**, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. *J Exp Clin Cancer Res* 2009; **28**: 93 [PMID: 19566940 DOI: 10.1186/1756-9966-28-93]

26 **Jiang H**, Wu L, Mishra M, Chawsheen HA, Wei Q. Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy. *Am J Cancer Res* 2014; **4**: 445-460 [PMID: 25232487]

27 **Gong F**, Hou G, Liu H, Zhang M. Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. *Med Oncol* 2015; **32**: 455 [PMID: 25579166 DOI: 10.1007/s12032-014-0455-0]

28 **Poddar S**, Kesharwani D, Datta M. Interplay between the miRNome and the epigenetic machinery: Implications in health and disease. *J Cell Physiol* 2017; **232**: 2938-2945 [PMID: 28112397 DOI: 10.1002/jcp.25819]

29 **Suzuki H**, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, Takamaru H, Niinuma T, Maruyama R, Yamamoto H, Tokino T, Imai K, Toyota M, Shinomura Y. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. *Carcinogenesis* 2010; **31**: 2066-2073 [PMID: 20924086 DOI: 10.1093/carcin/bgq203]

30 **Ramchandani S**, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal. *Proc Natl Acad Sci USA* 1999; **96**: 6107-6112 [PMID: 10339549]

31 **Lyko F**, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. *J Natl Cancer Inst* 2005; **97**: 1498-1506 [PMID: 16234563 DOI: 10.1093/jnci/dji311]

32 **Das PM**, Singal R. DNA methylation and cancer. *J Clin Oncol* 2004; **22**: 4632-4642 [PMID: 15542813 DOI: 10.1200/jco.2004.07.151]

33 **Mai A**, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. *Int J Biochem Cell Biol* 2009; **41**: 199-213 [PMID: 18790076 DOI: 10.1016/j.biocel.2008.08.020]

34 **Muraki Y**, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). *Oncol Rep* 2009; **22**: 967-972 [PMID: 19787208]

**P-Reviewer:** Dalay N, Kopljar M

**S-Editor:** Ma RY **L-Editor:** Wang TQ **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0



Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0


**Figure 1 MicroRNA-596 is downregulated and peroxiredoxin 1 upregulated in gastric cancer tissues and cell lines.**A and B: Expression of miR-596 in 55 pairs of gastric cancer (GC) and non-tumor tissues (A) and human GC cells (B). C and D: Expression of peroxiredoxin 1 (PRDX1) mRNA in 55 GC samples and corresponding non-tumor tissues (C) and human GC cells (D). E: Pearson's correlation analysis of the relative expression levels of miR‑596 and the relative PRDX1 mRNA expression levels in the same set of patients. β-actin was used as an internal control. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001 *vs* non-tumor tissues or GES-1. PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596.

**Figure 2 Peroxiredoxin 1 as a putative target of microRNA-596 in gastric cancer cells.** A: The predicted binding sites for microRNA-596 (miR-596) in the 3'-UTR of peroxiredoxin 1 (PRDX1). B: Expression of PRDX1 protein in human gastric cancer (GC) cells. C: Quantitative real-time PCR (qRT-PCR) for determining miR-596 expression in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimic. D: PRDX1 mRNA and protein expression in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimic. β-actin was used as an internal control. E: Relative luciferase activity of PRDX1 in wild-type (WT-UTR) or mutant (MUT-UTR). a*P* < 0.05, b*P* < 0.01, c*P* < 0.001 *vs* miR-NC. PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596.


****


**Figure 3 MicroRNA-596 suppresses gastric cancer cell proliferation.** NC, miR-NC, or miR-596 mimic was transfected into MKN-45 (A) and MGC-803 (B) cells. The cell growth rate was determined by measuring Cell Counting Kit-8 absorbance at 450 nm every 24 h (a*P* < 0.05, b*P* < 0.01 *vs* miR-NC).

**


**

**Figure 4 MicroRNA-596 inhibits gastric cancer cell migration and invasion.**A and B: The wound healing assay for detecting cell migration in MKN-45 (A) and MGC-803 (B) cells transfected with miR-NC or microRNA-596 (miR-596) mimic. C: The Transwell invasion assay for detecting cell invasion in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimic. a*P* < 0.05, b*P* < 0.01 *vs* miR-NC.

****

****

**Figure 5 MicroRNA-596 is regulated by epigenetic mechanisms in gastric cancer.** A: Methylation-specific PCR (MSP) analysis of microRNA-596 (miR-596) promoter region methylation in gastric cancer (GC) cell lines. B: Quantitative real-time PCR (qRT-PCR) and MSP analysis of miR-596 expression after treatment with 5-Aza-2’-deoxycytidine (5-Aza-dC) (2.5, 5, or 10 µmol/L) in MKN-45 and MGC-803 cells, a*P* < 0.05, b*P* < 0.01 *vs* control cells. C: qRT-PCR and Western blot analysis of PRDX1 expression after treatment with 5-Aza-dC (2.5, 5 or 10 µmol/L) in MKN-45 and MGC-803 cells, a*P* < 0.05, b*P* < 0.01 *vs* control cells. D: The promoter sequence of miR-596 after treatment with sodium bisulfate. Unmethylation of cytosine was transformed to uracil, but methylated cytosine remained unchanged. 1: DNA sequence of miR-596 promoter; 2: Sequence after sodium bisulfate modification; U: Unmethylation lane; M: Methylation lane; PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596; 5-Aza-Dc: 5-Aza-2’-deoxycytidine.

****

**Figure 6 5-Aza-2’-deoxycytidine treatment decreases proliferation in the MKN-45 (A) and MGC-803 (B) cells.**Inhibition rate (%) = (ODuntreated control - ODtreated) / ODuntreated control × 100%. 5-Aza-Dc: 5-Aza-2’-deoxycytidine.

**Table 1 Sequences of primers for quantitative real-time PCR**

|  |  |
| --- | --- |
| **Name** | **Sequence (5'-3')** |
| Primers used for mRNA detection |  |
| miR-596 (forward) | AAGCCTGCCCGGCTCCT |
| miR-596 (reverse) | GCTGTCAACGATACGCTACGT |
| miR-596 (RT) | (GCTGTCAACGATACGCTACGTAACGGCATGACA  GTGTTTTTTTTTTTTTTTTTTTTTTTTC) |
| U6 (forward) | CGCTTCGGCAGCACATATAC |
| U6 (reverse) | TTCACGAATTTGCGTG TCAT |
| U6 (RT) | (GCTGTCAACGATACGCTACGTAACGGCATGACAG TGTTTTTTTTTTTTTTTTTTTTTTTTG) |
| PRDX1 (forward) | AAGAAACTCAACTGCCAAGTG |
| PRDX1 (reverse) | CAGCCTTTAAGACCCCATAAT |
| GAPDH (forward) | CGGATTTGGTCGTATTGGG |
| GAPDH (reverse) | CTGGAAGATGGTGATGGGATT |

PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596; GAPDH: Glyceraldehyde phosphate dehydrogenase.

**Table 2 Correlation between microRNA-596 expression and clinicopathological variables of gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | | **No. of Patients** | **Low expression** | **High expression** | ***P*-value** |
| Age (yr) | |  |  |  | 0.667 |
| <60 | | 18 | 14 | 4 |  |
| ≥60 | | 37 | 32 | 5 |  |
| Gender | |  |  |  | 1.000 |
| Male | | 36 | 30 | 6 |  |
| Female | | 19 | 16 | 3 |  |
| Size (cm) | |  |  |  | 0.227 |
| <5 | | 18 | 13 | 5 |  |
| ≥5 | | 37 | 33 | 4 |  |
| Tumor differentiation | | |  |  | 0.043a |
| Well/moderate | | 23 | 16 | 7 |  |
| Poor | | 32 | 30 | 2 |  |
| Tumor location | |  |  |  | 0.827 |
| Upper | | 5 | 4 | 1 |  |
| Middle | | 12 | 11 | 1 |  |
| Lower | | 38 | 31 | 7 |  |
| Borrmann type | |  |  |  | 0.545 |
| I + II | | 6 | 4 | 2 |  |
| III + V | | 49 | 42 | 7 |  |
| TNM stage | |  |  |  | 0.031a |
| I+II | | 22 | 15 | 7 |  |
| III+IV | | 33 | 31 | 2 |  |
| Lymph node metastasis | | |  |  | 0.239 |
| No | 13 | | 9 | 4 |  |
| Yes | 42 | | 37 | 5 |  |

a*P* < 0.05.